Fig 1.
Flow of patient selection.
Fig 2.
Incidence of hepatocellular carcinoma in the study cohort.
Kaplan-Meier analysis showed that the cumulative risk of HCC was 0.7, 3.1, 5.8, 11.7% at 1, 3, 5, 10 years, respectively.
Table 1.
Baseline clinical and laboratory parameters in patients with or without subsequent HCC development during the surveillance period.
Table 2.
Multivariate logistic regression model for covariates of elevated AFP levels (> 10 ng/mL) during HCC surveillance.
Table 3.
Comparison of C statistics of AFP measurements according to covariates of AFP elevation and baseline AFP levels.
Table 4.
Covariate-adjusted ROC regression analysis of AFP for HCC surveillance.
Table 5.
Sensitivity and specificity of AFP according to concomitant albumin levels and NA therapy.
Fig 3.
Receiver operating characteristic curves of AFP according to NA therapy status and concomitant albumin levels.
The C statistics with 95% confidence interval are presented in brackets. AFP tests showed best performance in patients without NA therapy during study period and when concomitantly measured albumin levels were ≥ 3.7 g/dL. In contrast, the C statistics were lowest in patients who received NA therapy during study period and when concomitantly measured albumin levels were < 3.7 g/dL.